Are statins beneficial for CVD prevention in diabetics across all age groups?
Korea: According to a recent study in the journal Diabetes Research and Clinical Practice, statin use is protective against cardiovascular disease (CVD) and all-cause mortality in patients with type 2 diabetes (T2D). The protective effect, however, was reduced after the age of 75 years and disappeared in young patients <40 years.
People with type 2 diabetes are at increased risk of cardiovascular morbidity and mortality compared to those without diabetes. Statin is used for the prevention of coronary heart disease (CHD) in patients without a history of CVD (primary prevention) and those at very high risk of developing CVD including patients with diabetes, genetic familial hyperlipidemia.
You-Cheol Hwang, Kyung Hee University School of Medicine, Seoul, Republic of Korea, and colleagues in a propensity score-matched cohort analysis addressed the question of whether statin use is associated with a reduction in CVD and mortality in patients with T2D without pre-existing CVD.
For achieving their objective the researchers created a propensity score-matched cohort analysis using retrospective data. Statin users received at least a 90-day prescription and never used statin before initiation of the study. Statin non-users never received statin throughout the study.
The primary outcome was a composite of myocardial infarction (MI), stroke, and all-cause death, and the secondary outcome was an individual event.
The propensity score-matched cohort included 168,045 statin users and 168,045 non-users (mean age 57 years; median follow-up 5.0 years).
The analysis yielded the following findings:
- Compared to statin non-users, the hazard ratio (HR) was 0.72 for composite outcomes, 0.80 for MI, 0.74 for stroke, and 0.68 for all-cause death in statin users.
- The risk reduction was most prominent in subjects aged 40–74 years, attenuated but significant in those aged ≥75 years, and not significant in those aged <40 years.
Based on the findings, the researchers concluded, statin showed a protective effect against CVD and all-cause death in type 2 diabetes; this effect was reduced beyond the age of 75 years and disappeared in young patients aged <40 years.
Reference:
The study titled, "Statin use for primary prevention in patients with type 2 diabetes: Can it benefit all ages? – A nationwide propensity-matched cohort study," is published in the journal Diabetes Research and Clinical Practice.
DOI: https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(21)00403-4/fulltext
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.